Antiviral Drugs Market Comprehensive Statistics, Growth Rate, and Future Trends 2035
Date of Publication: 29 May 2025 - The newly released report titled ‘‘Antiviral Drugs Market’ offers a structured analysis of the current state and future outlook of the global market. Covering historical trends and future projections from 2025 to 2035, the study evaluates how the market size has shifted over time and what lies ahead in terms of growth and development. The report focuses on evidence-based trends, providing insights into demand shifts, market structure, and broader industry patterns.
The global antiviral drugs market size is estimated to grow from USD 65 billion in 2024 to reach USD 69 billion in 2025 and USD 127 billion by 2035, representing a higher CAGR of 6.2% during the forecast period. The report assesses this growth by examining real-world data, strategic decisions made by key companies, and movement across regional markets. Rather than making speculative forecasts, it presents information in a way that supports grounded business decision-making and planning.
The research investigates key elements influencing the market and offers a detailed breakdown of major operational categories. It explores business expansion efforts, investment themes, and product distribution strategies used across the industry. Readers are provided with a neutral overview of the ‘Antiviral Drugs Market forecast, grounded in verified insights rather than promotional narratives.
By Mechanism ofAction
Fusion Inhibitors
DNA Polymerases
Protease Inhibitors
Reverse Transcriptase
Others
By Target Indication
Human Immunodeficiency Virus Infection
Coronavirus Infection
Hepatitis
Herpes Simplex Virus Infection
Cytomegalovirus Infection
Influenza
Others
By Drug Target
Virus Targets
Host Targets
By Type of Therapy
Monotherapy
Combination Therapy
Key GeographicalRegions
North America
Europe
Asia Pacific
Latin America
Middle East and North Africa
Key Companies Profiled
AbbVie
AstraZeneca
Bristol-Myers Squibb
Genentech
Gilead Sciences
GlaxoSmithKline (GSK)
Johnson & Johnson
Merck
Novartis
Pfizer
Roche
ViiV Healthcare
Browse for more related reports
https://vi.anotepad.com/note/read/aawikw9h
https://github.com/koreylanson..../skills-github-pages
https://md.picasoft.net/s/qegSMUkSc
https://rv4tbvnoxdt.typeform.com/to/LnQpmcQP
http://g95183sh.bget.ru/blogs/....wearable-technology-
https://gitflic.ru/project/chr....isgayle22/roots2/iss
https://secure.smore.com/n/jwe....r7-ai-in-drug-discov
https://tree.taiga.io/project/....chrisgayle22-roots/i
https://git.octree.ch/decidim/....vocacity/decidim-mod
https://git.parscoders.com/chr....is0010/roots/-/issue
https://viblo.asia/p/ai-in-dru....g-discovery-market-s
https://tildegit.org/chris666669/Roots/issues/5
https://docs.aix.inrae.fr/s/uqu4NzVUy
The report includes a dedicated analysis of major players contributing to the ‘Antiviral Drugs Market growth. Some of the top companies in ‘Antiviral Drugs include AbbVie , AstraZeneca , Bristol-Myers Squibb , Genentech, Gilead Sciences, GlaxoSmithKline (GSK), Johnson & Johnson, Merck, Novartis , Pfizer, Roche , ViiV Healthcare.
These organizations have been profiled in terms of their operational scale, product offerings, and strategic initiatives. Their positions in regional and global markets are discussed with reference to product performance, market engagement, and business continuity strategies. The report highlights how these players have shaped the market over time, offering insight into their long-term direction and business focus.
